Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III subcutaneous cluster immunotherapy study in house dust mite allergy
2024-517014-15-00Phase 3Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of dermatophagoides pteronyssinus allergoid (glutaraldehyde-modified) in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy (4 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Mean Combined Symptom and Medication Score during peak mite period. Started Mar 2025; status: completed.
02
Drugs
dermatophagoides pteronyssinus allergoid (glutaraldehyde-modified)
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2024-517014-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517014-15-00.